Searched for
MEDICINE STOCK
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsFrom a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Hormuz halt forces Middle East trade into huge rewiringA year after a US-Israel and Iran conflict, Siemens Energy explored alternative routes to Dammam, Saudi Arabia, due to potential Strait of ...
- Nifty’s hidden discount sale: 54% of top Indian stocks are cheaper now than in 2023. Is it time to buy?Over half of India's top Nifty50 stocks are now trading at lower forward P/E multiples than in 2023, indicating a significant valuation cor...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26%On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...
- European shares rally as Middle East peace hopes drag oil prices lowerEuropean shares surged on Friday, driven by renewed hopes for a Middle East diplomatic breakthrough that lowered oil prices. The pan-Europe...
- Global Market | European stocks rally as oil falls on hopes for US-Iran dealThe benchmark snapped a four-day losing streak on Thursday, as investors digested the European Central Bank's rate hike and largely looked...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Nifty in control of FIIs? The unlucky 13 bluechips facing the hardest institutional selloffForeign investors have significantly reduced holdings in many Nifty companies since September 2024. This has impacted top blue-chip stocks,...
- Japanese investors are looking beyond China... India is key alternative: Tsutomu Takemura, Senior MD, NomuraIndia is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Saurabh Mukherjea’s global strategy: How Marcellus is hunting compounder stocks across 4 multi-trillion dollar megatrendsSaurabh Mukherjea of Marcellus is avoiding AI giants like Nvidia, instead focusing on companies enabling AI's physical infrastructure. His ...
- 5 mid-cap stocks from different sectors with an upside potential of 13 to 24% in one year, according to analystsWhen mid-caps were rising, every concern on valuation was treated as unnecessary caution. Investors who advised patience were told they wer...
- DIIs' net purchases cross Rs 4 lakh crore on Dalal Street in 2026 while FIIs run awayDomestic institutional investors (DIIs) have remained strong buyers of Indian equities in 2026, with net purchases crossing Rs 4.16 lakh cr...
- Explained: How AI mania has thrown India Inc out of MSCI EM's top 10 and world's top 100 listIndian companies are no longer in the top 10 of the MSCI Emerging Markets Index. A surge in AI stocks has shifted global capital. Taiwan an...
- IndiGo shares gain 2% after analyst meet. Why Goldman, Morgan Stanley, others see up to 38% upside?IndiGo shares witnessed an uptick on Tuesday after its analyst meet, where management outlined strong long-term growth plans driven by risi...
- Wipro's Rs 15,000-crore buyback opens June 11; entitlement ratio and key details announcedIT major Wipro's Rs 15,000-crore share buyback offer will commence on June 11 and conclude on June 17, 2026. Small shareholders can tender ...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 26%Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...
- Good news for diabetes & BP patients: Govt cuts prices of these 30 medicines, relief may reach pharmacies soonThe National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 30 essential drug formulations, including those for diabet...
Load More
